Every compound named here is supplied strictly as a laboratory research material. None is approved, intended or authorised for human consumption, none is an FDA- or MHRA-approved medicine, and nothing below is a protocol, dosing guidance or medical advice. This is a summary of research directions for qualified researchers only.
The lean-mass problem
Body weight is a mix of fat mass and fat-free (lean) mass — muscle, organ tissue and water. When weight comes off, some proportion of what is lost is lean tissue; the faster and larger the loss, the more that becomes a research concern. As incretin agonists such as semaglutide, tirzepatide and the investigational retatrutide push the magnitude of modelled weight loss higher, the field's attention has shifted from how much weight changes to the composition of that change. "Quality of weight loss" — the fat-to-lean ratio — is now a headline endpoint, not a footnote.
This is why a metabolic story has, somewhat unexpectedly, become a muscle story too. Two research avenues sit at the centre of it: the growth-hormone axis, and the myostatin/activin pathway.
The growth-hormone axis angle
The GH/IGF-1 axis is the body's classic anabolic signalling system, so it is the obvious first place to look for counterweights to lean-mass loss. Two families of research peptides act on it from different ends:
| Peptide | Class | How it acts on the GH axis |
|---|---|---|
| Sermorelin | GHRH analogue (GRF 1–29) | Stimulates the pituitary to release GH; short, natural-shaped pulse |
| CJC-1295 | GHRH analogue (± DAC) | Longer-acting GHRH signal; DAC extends action via albumin binding |
| Tesamorelin | Stabilised GHRH analogue | Studied specifically in visceral-fat / body-composition research |
| Ipamorelin | GH secretagogue (GHS-R1a) | Selective, pulsatile GH release with minimal cortisol/prolactin |
All are investigational research compounds. None is FDA-approved or authorised for human use.
The GHRH analogues (Sermorelin, CJC-1295, Tesamorelin) work upstream, nudging the pituitary's own release machinery, while GH secretagogues like Ipamorelin act through the ghrelin receptor to trigger discrete GH pulses. They are frequently studied as a pair — a GHRH analogue plus a secretagogue — because the two mechanisms are complementary; see CJC-1295 vs Ipamorelin and Sermorelin vs Ipamorelin. Of the group, Tesamorelin is the one with the most body-composition-specific research history, which is exactly why it re-enters the conversation here.
The myostatin / activin pathway
The second avenue targets the brake rather than the accelerator. Myostatin (and the broader activin–ActRII signalling system) is a negative regulator of muscle growth: less myostatin signalling, more muscle-building capacity, at least in animal models. Interest in inhibiting this pathway to protect lean mass during rapid fat loss has grown sharply, and it is increasingly discussed as a potential complement to incretin research rather than a rival to it. This remains an earlier-stage, largely preclinical area — worth watching, not overselling.
Where this is heading: combinations
The through-line of what's new in peptides this autumn is combination research, and muscle preservation is a clear example. The open questions being modelled are things like: does pairing an incretin with a GH-axis peptide shift the fat-to-lean ratio of weight change? Does myostatin-pathway modulation preserve muscle without blunting fat loss? These are research questions with preclinical, not human, answers so far — but they are among the most active in the field.
The bottom line
Rapid incretin-driven weight loss has made lean-mass preservation one of the most interesting secondary questions in metabolic research. The growth-hormone axis — via GHRH analogues and selective secretagogues — and the myostatin/activin pathway are the two avenues drawing the most attention as potential counterweights. As always, the honest framing is the important part: these are investigational research compounds for in vitro use only, the supporting data is largely preclinical, and none is an approved treatment. For the mechanisms in full, start with the Tesamorelin and Ipamorelin profiles in the knowledgebase.
